An aqueous extract of tropical bamboo reduced stress-related gene activity and improved blood glucose in diabetic rats, while computer modelling identified several compounds that could interact with the PERK pathway.
Researchers reporting in Molecular Biology Reports say an aqueous extract of Bambusa vulgaris, a tropical bamboo long used in traditional medicine, reduced genes linked to endoplasmic reticulum stress in diabetic rats and showed promising binding in computer models to a key stress-related protein. The study, led by Yetunde Victoria Aladenika and colleagues, combines animal data with molecular docking to explore a possible mechanism behind the plant’s reported antidiabetic effects.
In the experiment, the team induced endoplasmic reticulum stress in 30 rats with streptozotocin, a compound commonly used to create diabetes-like conditions in laboratory animals. The rats were split into six groups: one control group, one untreated stress group, one given metformin, and three treated with different doses of the bamboo extract. Over 21 days, the researchers monitored fasting blood glucose and measured gene expression, focusing on four markers of stress inside the cell’s protein-folding machinery: GRP78, CHOP, ATF4 and PERK.
Within three days of streptozotocin exposure, the stress markers were sharply elevated, the authors said. Treatment with the bamboo extract at 50mg/kg and 100mg/kg brought down the expression of those genes compared with untreated stressed rats, and the extract also appeared to improve blood glucose levels. The highest dose, 200mg/kg, was not highlighted in the abstract as producing the same level of gene suppression.
The paper then turned to computer-based screening of compounds found in Bambusa vulgaris. Using Schrödinger software, the researchers docked several phytochemicals against PERK, a protein central to one branch of the unfolded protein response, the cellular system that manages endoplasmic reticulum stress. Luteolin and chlorogenic acid recorded strong docking scores, while isovitexin showed the most favourable calculated free binding energy in the analysis. The compounds also met Lipinski’s rule of five, a set of guidelines often used to judge whether a molecule may have drug-like properties.
The broader science behind the study is well established. Research over the past decade has linked prolonged endoplasmic reticulum stress to diabetic kidney disease, pancreatic beta-cell injury and other metabolic complications, and reviews have identified GRP78, PERK, IRE1 and ATF6 as major nodes in that pathway. Other laboratory studies have also suggested that plant-derived compounds can ease stress signalling in diabetes models, including work on lemongrass extract in rats and a separate study of atractylenolide III in heart cells. Against that backdrop, the bamboo findings add another possible candidate to a crowded field of natural products being examined for metabolic benefit.
Even so, the authors’ results remain preliminary. The animal groups were small, the experiment was short, and the docking work shows theoretical binding rather than direct biological inhibition in living tissue. The study does not establish that Bambusa vulgaris would work in people, nor does it address long-term safety, but it does offer a testable starting point for further laboratory research into how the plant’s compounds may interact with ER-stress pathways in diabetes.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
